Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells (Q37003558)

From Wikidata

Jump to navigation Jump to search

scientific article published on 04 September 2008

Language	Label	Description	Also known as
English	Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells	scientific article published on 04 September 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

15

object named as

Guido Marcucci

1 reference

Europe PubMed Central

17 August 2017

PMC publication ID

20

object named as

John C Byrd

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

9

object named as

William Blum

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Natarajan Muthusamy

19

object named as

Natarajan Muthusamy

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Leslie A Andritsos

10

object named as

Leslie Andritsos

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Gerard Lozanski

6

object named as

Gerard Lozanski

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Shih-Ching Chen

13

object named as

Ching-Shih Chen

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

7

object named as

Asha Ramanunni

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Rosa Lapalombella

1

object named as

Rosa Lapalombella

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

12

object named as

Amy Lehman

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

author name string

Bo Yu

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Georgia Triantafillou

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Qing Liu

4

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Jonathan P Butchar

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Lisa L Smith

8

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Da-Sheng Wang

11

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Amy J Johnson

14

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Robert J Lee

16

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

L James Lee

17

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Susheela Tridandapani

18

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

language of work or name

0 references

publication date

4 September 2008

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

112

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

13

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

5180-5189

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Immunomodulating drugs for chronic lymphocytic leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Antibody therapy for chronic lymphocytic leukemia: a promising new modality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Protein G: a powerful tool for binding and detection of monoclonal and polyclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Expression of the human B-cell surface protein CD20: alteration by phorbol 12-myristate 13-acetate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

4 September 2018

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

4 September 2018

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

4 September 2018

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Down-regulation of CD20 on B cells upon CD40 activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decreased antibody-dependent cellular cytotoxicity in various types of leukaemia in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A physicochemical study of protein G, a molecule with unique immunoglobulin G-binding properties

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group fo

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2008-01-133108

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37003558&oldid=2158839317"